$USNU
Elite Health Systems Inc.

2021 Q4 Form 10-K Financial Statement

#000114036122014709 Filed on April 15, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 2020 Q4
Revenue $0.00 $1.061M $1.168M
YoY Change -100.0% -66.56% 56.57%
Cost Of Revenue $0.00 $86.00K $85.00K
YoY Change -100.0% -76.18% -15.84%
Gross Profit $0.00 $975.0K $1.083M
YoY Change -100.0% -65.33% 67.91%
Gross Profit Margin 91.89% 92.72%
Selling, General & Admin $248.0K $1.064M $256.0K
YoY Change -3.13% -11.11% -5.19%
% of Gross Profit 109.13% 23.64%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $248.0K $1.150M $256.0K
YoY Change -3.13% -26.19% -5.19%
Operating Profit -$248.0K -$89.00K $827.0K
YoY Change -129.99% -105.51% 120.53%
Interest Expense -$120.0K $3.000K -$503.0K
YoY Change -76.14% -88.0% -11.6%
% of Operating Profit -60.82%
Other Income/Expense, Net -$9.000K -$465.0K
YoY Change -38.74%
Pretax Income -$377.0K -$554.0K $324.0K
YoY Change -216.36% -164.72% -267.01%
Income Tax $218.0K $120.0K $175.0K
% Of Pretax Income 54.01%
Net Earnings -$503.0K -$627.0K $149.0K
YoY Change -437.58% -217.64% -249.0%
Net Earnings / Revenue -59.1% 12.76%
Basic Earnings Per Share -$0.08
Diluted Earnings Per Share -$64.55K -$0.08 $19.12K
COMMON SHARES
Basic Shares Outstanding 7.792M
Diluted Shares Outstanding 7.792M

Balance Sheet

Concept 2021 Q4 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.178M $2.178M $2.030M
YoY Change 7.29% 7.29% 52.06%
Cash & Equivalents $2.178M $2.178M $2.030M
Short-Term Investments
Other Short-Term Assets $65.00K $65.00K $99.00K
YoY Change -34.34% -34.34% -2.94%
Inventory
Prepaid Expenses
Receivables $0.00 $0.00 $346.0K
Other Receivables $0.00 $0.00 $532.0K
Total Short-Term Assets $2.243M $2.243M $3.007M
YoY Change -25.41% -25.41% 12.16%
LONG-TERM ASSETS
Property, Plant & Equipment $59.00K $59.00K $94.00K
YoY Change -37.23% -37.23% -26.56%
Goodwill $315.0K $0.00
YoY Change
Intangibles
YoY Change
Long-Term Investments $141.0K $141.0K $160.0K
YoY Change -11.88% -11.88% -10.61%
Other Assets $1.386M $930.0K $1.072M
YoY Change 29.29% 1.97% -51.01%
Total Long-Term Assets $1.445M $1.445M $1.166M
YoY Change 23.93% 23.93% -49.65%
TOTAL ASSETS
Total Short-Term Assets $2.243M $2.243M $3.007M
Total Long-Term Assets $1.445M $1.445M $1.166M
Total Assets $3.688M $3.688M $4.173M
YoY Change -11.62% -11.62% -16.49%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $169.0K $169.0K
YoY Change -0.59%
Accrued Expenses $43.00K $43.00K $40.00K
YoY Change 7.5% 7.5% 11.11%
Deferred Revenue $0.00
YoY Change -100.0%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $89.00K
YoY Change -100.0% -100.0% -90.12%
Total Short-Term Liabilities $626.0K $626.0K $410.0K
YoY Change 52.68% 52.68% -74.97%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $34.00K $34.00K $77.00K
YoY Change -55.84% -55.84% -34.19%
Total Long-Term Liabilities $34.00K $34.00K $77.00K
YoY Change -55.84% -55.84% -62.62%
TOTAL LIABILITIES
Total Short-Term Liabilities $626.0K $626.0K $410.0K
Total Long-Term Liabilities $34.00K $34.00K $77.00K
Total Liabilities $660.0K $1.112M $487.0K
YoY Change 35.52% 128.34% -73.59%
SHAREHOLDERS EQUITY
Retained Earnings -$373.0K $508.0K
YoY Change -173.43% -2132.0%
Common Stock $2.949M $3.178M
YoY Change -7.21% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.576M $2.576M $3.686M
YoY Change
Total Liabilities & Shareholders Equity $3.688M $3.688M $4.173M
YoY Change -11.62% -11.62% -16.49%

Cashflow Statement

Concept 2021 Q4 2021 2020 Q4
OPERATING ACTIVITIES
Net Income -$503.0K -$627.0K $149.0K
YoY Change -437.58% -217.64% -249.0%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$268.0K $174.0K $595.0K
YoY Change -145.04% -84.42% 27.68%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$121.0K $63.00K $22.00K
YoY Change -650.0% -86.85% -113.75%
Cash From Investing Activities -$121.0K $63.00K $22.00K
YoY Change -650.0% -86.85% -113.75%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 -89.00K -87.00K
YoY Change -100.0% -90.12% -76.03%
NET CHANGE
Cash From Operating Activities -268.0K 174.0K 595.0K
Cash From Investing Activities -121.0K 63.00K 22.00K
Cash From Financing Activities 0.000 -89.00K -87.00K
Net Change In Cash -389.0K 148.0K 530.0K
YoY Change -173.4% -78.71% -1029.82%
FREE CASH FLOW
Cash From Operating Activities -$268.0K $174.0K $595.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001089815
CY2021 dei Auditor Firm
AuditorFirmId
517
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
0-15586
CY2021 dei Entity Registrant Name
EntityRegistrantName
U.S. NeuroSurgical Holdings, Inc.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-5370333
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
2400 Research Blvd, Suite 325
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Rockville
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
MD
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
20850
CY2021 dei City Area Code
CityAreaCode
301
CY2021 dei Local Phone Number
LocalPhoneNumber
208-8998
CY2021 dei Security12g Title
Security12gTitle
Common Stock, par value $.01 per share
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
1257000
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
7792185
CY2021 dei Auditor Name
AuditorName
Aronson LLC
CY2021 dei Auditor Location
AuditorLocation
Rockville, Maryland
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
346000
CY2021Q4 us-gaap Net Investment In Lease Current
NetInvestmentInLeaseCurrent
0
CY2020Q4 us-gaap Net Investment In Lease Current
NetInvestmentInLeaseCurrent
532000
CY2021Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
0
CY2020Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
89000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7792185
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7792185
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7792185
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7792185
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-759000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-554000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
856000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
120000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
323000
CY2021 us-gaap Profit Loss
ProfitLoss
-674000
CY2020 us-gaap Profit Loss
ProfitLoss
533000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1061000
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3173000
CY2021 us-gaap Health Care Organization Expenses Net
HealthCareOrganizationExpensesNet
86000
CY2020 us-gaap Health Care Organization Expenses Net
HealthCareOrganizationExpensesNet
361000
CY2021 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1064000
CY2020 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1197000
CY2021 us-gaap Operating Expenses
OperatingExpenses
1150000
CY2020 us-gaap Operating Expenses
OperatingExpenses
1558000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-89000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
1615000
CY2021 us-gaap Interest Expense
InterestExpense
3000
CY2020 us-gaap Interest Expense
InterestExpense
25000
CY2021 us-gaap Investment Income Interest
InvestmentIncomeInterest
0
CY2020 us-gaap Investment Income Interest
InvestmentIncomeInterest
3000
CY2021 us-gaap Sales Type Lease Interest Income
SalesTypeLeaseInterestIncome
8000
CY2020 us-gaap Sales Type Lease Interest Income
SalesTypeLeaseInterestIncome
72000
CY2021 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-470000
CY2020 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-809000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-465000
CY2021 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-47000
CY2020 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-627000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
533000
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.08
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.08
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.07
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.07
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7792185
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7792185
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7792185
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7792185
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
3153000
CY2020 us-gaap Profit Loss
ProfitLoss
533000
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
3686000
CY2021 us-gaap Noncontrolling Interest Increase From Subsidiary Equity Issuance
NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
315000
CY2021 us-gaap Profit Loss
ProfitLoss
-674000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
3327000
CY2021 us-gaap Profit Loss
ProfitLoss
-674000
CY2020 us-gaap Profit Loss
ProfitLoss
533000
CY2021 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
35000
CY2020 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
34000
CY2021 usnu Income Loss From Equity Method Investments Net
IncomeLossFromEquityMethodInvestmentsNet
-470000
CY2020 usnu Income Loss From Equity Method Investments Net
IncomeLossFromEquityMethodInvestmentsNet
-809000
CY2021 us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
0
CY2020 us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
176000
CY2021 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
0
CY2020 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
0
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2020 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
17000
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-346000
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-10000
CY2021 us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
3000
CY2020 us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
-109000
CY2021 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-34000
CY2020 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
6000
CY2021 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
0
CY2020 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-85000
CY2021 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0
CY2020 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-226000
CY2021 usnu Increase Decrease In Operating Lease Right Of Use Liability
IncreaseDecreaseInOperatingLeaseRightOfUseLiability
40000
CY2020 usnu Increase Decrease In Operating Lease Right Of Use Liability
IncreaseDecreaseInOperatingLeaseRightOfUseLiability
36000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
174000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1117000
CY2021 us-gaap Payments For Advance To Affiliate
PaymentsForAdvanceToAffiliate
491000
CY2020 us-gaap Payments For Advance To Affiliate
PaymentsForAdvanceToAffiliate
459000
CY2021 us-gaap Payments For Proceeds From Loans Receivable
PaymentsForProceedsFromLoansReceivable
-22000
CY2020 us-gaap Payments For Proceeds From Loans Receivable
PaymentsForProceedsFromLoansReceivable
-175000
CY2021 us-gaap Payments To Acquire Businesses And Interest In Affiliates
PaymentsToAcquireBusinessesAndInterestInAffiliates
0
CY2020 us-gaap Payments To Acquire Businesses And Interest In Affiliates
PaymentsToAcquireBusinessesAndInterestInAffiliates
125000
CY2021 us-gaap Proceeds From Collection Of Lease Receivables
ProceedsFromCollectionOfLeaseReceivables
532000
CY2020 us-gaap Proceeds From Collection Of Lease Receivables
ProceedsFromCollectionOfLeaseReceivables
888000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
63000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
479000
CY2021 us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
89000
CY2020 us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
901000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-89000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-901000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
148000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
695000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2030000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1335000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2178000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2030000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
3000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
25000
CY2021 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
213000
CY2020 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
419000
CY2021 usnu Conversion Of Advance To Unconsolidated Entity In Lieu Of Cash Payment For Capital Contribution
ConversionOfAdvanceToUnconsolidatedEntityInLieuOfCashPaymentForCapitalContribution
0
CY2020 usnu Conversion Of Advance To Unconsolidated Entity In Lieu Of Cash Payment For Capital Contribution
ConversionOfAdvanceToUnconsolidatedEntityInLieuOfCashPaymentForCapitalContribution
121000
CY2021 us-gaap Other Significant Noncash Transaction Value Of Consideration Given1
OtherSignificantNoncashTransactionValueOfConsiderationGiven1
315000
CY2020 us-gaap Other Significant Noncash Transaction Value Of Consideration Given1
OtherSignificantNoncashTransactionValueOfConsiderationGiven1
0
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2000000
CY2020 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
12000
CY2021 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0
CY2021Q4 us-gaap Net Investment In Lease Current
NetInvestmentInLeaseCurrent
0
CY2020Q4 us-gaap Net Investment In Lease Current
NetInvestmentInLeaseCurrent
532000
CY2021Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
0
CY2020Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
89000
CY2020 us-gaap Lease Income
LeaseIncome
7000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
46000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
24000
CY2018Q3 us-gaap Sales Type Lease Lease Receivable
SalesTypeLeaseLeaseReceivable
2447000
CY2021 usnu Renovation Installation And Operation Agreement Period
RenovationInstallationAndOperationAgreementPeriod
P14Y
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
346000
CY2021 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
56000
CY2020 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
211000
CY2021 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
64000
CY2020 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
95000
CY2021 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
120000
CY2020 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
306000
CY2021 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
423000
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
79000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
120000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
323000
CY2020 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
5000
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2020 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
17000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
120000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
323000
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-130000
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
180000
CY2021 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-103000
CY2020 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
52000
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
-72000
CY2020 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
16000
CY2021 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
2000
CY2020 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
-4000
CY2021Q4 us-gaap Deferred Tax Assets Equity Method Investments
DeferredTaxAssetsEquityMethodInvestments
587000
CY2020Q4 us-gaap Deferred Tax Assets Equity Method Investments
DeferredTaxAssetsEquityMethodInvestments
561000
CY2021Q4 usnu Deferred Tax Assets Excess Of Depreciation Over Tax Depreciation
DeferredTaxAssetsExcessOfDepreciationOverTaxDepreciation
306000
CY2020Q4 usnu Deferred Tax Assets Excess Of Depreciation Over Tax Depreciation
DeferredTaxAssetsExcessOfDepreciationOverTaxDepreciation
192000
CY2021Q4 usnu Deferred Tax Assets Intangible Assets And Other Capitalized Costs
DeferredTaxAssetsIntangibleAssetsAndOtherCapitalizedCosts
102000
CY2020Q4 usnu Deferred Tax Assets Intangible Assets And Other Capitalized Costs
DeferredTaxAssetsIntangibleAssetsAndOtherCapitalizedCosts
0
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
66000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
34000
CY2021Q4 usnu Deferred Tax Assets Net Effect Of Conversion From Accrual Basis Of Accounting To Cash Basis
DeferredTaxAssetsNetEffectOfConversionFromAccrualBasisOfAccountingToCashBasis
44000
CY2020Q4 usnu Deferred Tax Assets Net Effect Of Conversion From Accrual Basis Of Accounting To Cash Basis
DeferredTaxAssetsNetEffectOfConversionFromAccrualBasisOfAccountingToCashBasis
0
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
502000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
79000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
603000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
708000
CY2021Q4 us-gaap Deferred Tax Liabilities Tax Deferred Income
DeferredTaxLiabilitiesTaxDeferredIncome
603000
CY2020Q4 us-gaap Deferred Tax Liabilities Tax Deferred Income
DeferredTaxLiabilitiesTaxDeferredIncome
634000
CY2021Q4 usnu Deferred Tax Liability Net Effect Of Conversion From Accrual Basis Of Accounting To Cash Basis
DeferredTaxLiabilityNetEffectOfConversionFromAccrualBasisOfAccountingToCashBasis
0
CY2020Q4 usnu Deferred Tax Liability Net Effect Of Conversion From Accrual Basis Of Accounting To Cash Basis
DeferredTaxLiabilityNetEffectOfConversionFromAccrualBasisOfAccountingToCashBasis
74000
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2019 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
176000
CY2019 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
161000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
66000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
59000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
106000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
94000
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
41000
CY2020 us-gaap Operating Lease Expense
OperatingLeaseExpense
42000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
46000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
24000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
70000
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
4000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
66000
CY2021 usnu Warranty Term Of Maintenance Agreement
WarrantyTermOfMaintenanceAgreement
P1Y
CY2015Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
20000
CY2017Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
26000
CY2021 usnu Maintenance Agreement
MaintenanceAgreement
P5Y
CY2021 us-gaap Malpractice Insurance Annual Coverage Limit
MalpracticeInsuranceAnnualCoverageLimit
3000000
CY2020 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
14000
CY2021 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0

Files In Submission

Name View Source Status
0001140361-22-014709-index-headers.html Edgar Link pending
0001140361-22-014709-index.html Edgar Link pending
0001140361-22-014709.txt Edgar Link pending
0001140361-22-014709-xbrl.zip Edgar Link pending
brhc10036299_10k.htm Edgar Link pending
brhc10036299_10k_htm.xml Edgar Link completed
brhc10036299_ex31-1.htm Edgar Link pending
brhc10036299_ex32-1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
usnu-20211231.xsd Edgar Link pending
usnu-20211231_cal.xml Edgar Link unprocessable
usnu-20211231_def.xml Edgar Link unprocessable
usnu-20211231_lab.xml Edgar Link unprocessable
usnu-20211231_pre.xml Edgar Link unprocessable